FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515727544> ?p ?o ?g. }

• W2515727544 endingPage "956" @default.
• W2515727544 startingPage "946" @default.
• W2515727544 abstract "Summary Background Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) therapy have shown high sustained virologic response (SVR) rates and good tolerability in most patient populations in pre‐registration studies. Aim To confirm these clinical trial findings in the treatment of genotype 1 and 4 hepatitis C under real‐world conditions. Methods Patients enrolled for treatment with OBV/PTV/r ± DSV ± RBV based on therapeutic guidelines were included, and the regimen was administered according to product characteristics. Clinical and laboratory data, including virologic response, were collected at baseline, end of treatment (EOT) and 12 weeks after EOT. Results A total of 209 patients with chronic hepatitis C were enrolled, most were genotype 1b‐infected (84.2%) and 119 (56.9%) had liver cirrhosis. Among these, 150 (71.7%) had failed previous anti‐viral therapies and 84 (40.2%) were null‐responders. At 12 weeks after EOT, SVR was achieved by 207 (99.0%) patients, ranging from 96.4% to 100.0% across subgroups. All Child–Pugh B and post‐orthotopic liver transplantation patients achieved SVR. Adverse events occurred in 151 (72.2%) patients and were mostly mild and associated with the use of RBV. Serious adverse events, including hepatic decompensation, renal insufficiency, anaemia, hepatotoxicity and diarrhoea, were reported in eight (3.8%) patients. In five (2.4%) patients, adverse events led to treatment discontinuation. On‐treatment decompensation was experienced by seven (3.3%) patients. Conclusions The results of our study confirm previous findings. They demonstrate excellent effectiveness and a good safety profile of OBV/PTV/r± DSV±RBV in HCV genotype 1‐infected patients treated in the real‐world setting." @default.
• W2515727544 created "2016-09-16" @default.
• W2515727544 creator A5003885788 @default.
• W2515727544 creator A5004476613 @default.
• W2515727544 creator A5014512426 @default.
• W2515727544 creator A5015515005 @default.
• W2515727544 creator A5020416987 @default.
• W2515727544 creator A5024429237 @default.
• W2515727544 creator A5024760069 @default.
• W2515727544 creator A5034070408 @default.
• W2515727544 creator A5040261650 @default.
• W2515727544 creator A5042837669 @default.
• W2515727544 creator A5043306295 @default.
• W2515727544 creator A5044604122 @default.
• W2515727544 creator A5045884774 @default.
• W2515727544 creator A5050789916 @default.
• W2515727544 creator A5051712335 @default.
• W2515727544 creator A5052693505 @default.
• W2515727544 creator A5055297251 @default.
• W2515727544 creator A5056497086 @default.
• W2515727544 creator A5057868472 @default.
• W2515727544 creator A5058746547 @default.
• W2515727544 creator A5071607313 @default.
• W2515727544 creator A5073695214 @default.
• W2515727544 creator A5078642431 @default.
• W2515727544 creator A5087321301 @default.
• W2515727544 creator A5088489771 @default.
• W2515727544 creator A5088500414 @default.
• W2515727544 creator A5089134320 @default.
• W2515727544 creator A5090928139 @default.
• W2515727544 creator A5091573769 @default.
• W2515727544 date "2016-09-09" @default.
• W2515727544 modified "2023-10-05" @default.
• W2515727544 title "Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study" @default.
• W2515727544 cites W1211669045 @default.
• W2515727544 cites W1687454876 @default.
• W2515727544 cites W1756460431 @default.
• W2515727544 cites W1963484557 @default.
• W2515727544 cites W1965358723 @default.
• W2515727544 cites W1973675889 @default.
• W2515727544 cites W1973920659 @default.
• W2515727544 cites W2035463434 @default.
• W2515727544 cites W2036913245 @default.
• W2515727544 cites W2069465518 @default.
• W2515727544 cites W2113636405 @default.
• W2515727544 cites W2114985397 @default.
• W2515727544 cites W2140481064 @default.
• W2515727544 cites W2164439784 @default.
• W2515727544 cites W2324515674 @default.
• W2515727544 cites W2340307424 @default.
• W2515727544 cites W2406348976 @default.
• W2515727544 cites W2411176684 @default.
• W2515727544 cites W2490846324 @default.
• W2515727544 cites W2523243208 @default.
• W2515727544 cites W2523477828 @default.
• W2515727544 cites W4231590131 @default.
• W2515727544 cites W4241616429 @default.
• W2515727544 doi "https://doi.org/10.1111/apt.13790" @default.
• W2515727544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27611776" @default.
• W2515727544 hasPublicationYear "2016" @default.
• W2515727544 type Work @default.
• W2515727544 sameAs 2515727544 @default.
• W2515727544 citedByCount "79" @default.
• W2515727544 countsByYear W25157275442016 @default.
• W2515727544 countsByYear W25157275442017 @default.
• W2515727544 countsByYear W25157275442018 @default.
• W2515727544 countsByYear W25157275442019 @default.
• W2515727544 countsByYear W25157275442020 @default.
• W2515727544 countsByYear W25157275442021 @default.
• W2515727544 countsByYear W25157275442022 @default.
• W2515727544 countsByYear W25157275442023 @default.
• W2515727544 crossrefType "journal-article" @default.
• W2515727544 hasAuthorship W2515727544A5003885788 @default.
• W2515727544 hasAuthorship W2515727544A5004476613 @default.
• W2515727544 hasAuthorship W2515727544A5014512426 @default.
• W2515727544 hasAuthorship W2515727544A5015515005 @default.
• W2515727544 hasAuthorship W2515727544A5020416987 @default.
• W2515727544 hasAuthorship W2515727544A5024429237 @default.
• W2515727544 hasAuthorship W2515727544A5024760069 @default.
• W2515727544 hasAuthorship W2515727544A5034070408 @default.
• W2515727544 hasAuthorship W2515727544A5040261650 @default.
• W2515727544 hasAuthorship W2515727544A5042837669 @default.
• W2515727544 hasAuthorship W2515727544A5043306295 @default.
• W2515727544 hasAuthorship W2515727544A5044604122 @default.
• W2515727544 hasAuthorship W2515727544A5045884774 @default.
• W2515727544 hasAuthorship W2515727544A5050789916 @default.
• W2515727544 hasAuthorship W2515727544A5051712335 @default.
• W2515727544 hasAuthorship W2515727544A5052693505 @default.
• W2515727544 hasAuthorship W2515727544A5055297251 @default.
• W2515727544 hasAuthorship W2515727544A5056497086 @default.
• W2515727544 hasAuthorship W2515727544A5057868472 @default.
• W2515727544 hasAuthorship W2515727544A5058746547 @default.
• W2515727544 hasAuthorship W2515727544A5071607313 @default.
• W2515727544 hasAuthorship W2515727544A5073695214 @default.
• W2515727544 hasAuthorship W2515727544A5078642431 @default.
• W2515727544 hasAuthorship W2515727544A5087321301 @default.
• W2515727544 hasAuthorship W2515727544A5088489771 @default.
• W2515727544 hasAuthorship W2515727544A5088500414 @default.

• next